Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza (CAPSTONE 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02954354
Recruitment Status : Completed
First Posted : November 3, 2016
Results First Posted : December 14, 2018
Last Update Posted : May 8, 2019
Sponsor:
Information provided by (Responsible Party):
Shionogi Inc. ( Shionogi )

Tracking Information
First Submitted Date  ICMJE October 27, 2016
First Posted Date  ICMJE November 3, 2016
Results First Submitted Date  ICMJE November 20, 2018
Results First Posted Date  ICMJE December 14, 2018
Last Update Posted Date May 8, 2019
Actual Study Start Date  ICMJE December 8, 2016
Actual Primary Completion Date April 4, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 20, 2018)
  • Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier (KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
  • Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Original Primary Outcome Measures  ICMJE
 (submitted: November 1, 2016)
Time to alleviation of symptoms [ Time Frame: From Day 1 pretreatment (baseline) up to Day 14 ]
Time to alleviation of symptoms is defined as the time between the initiation of the study treatment and the alleviation of influenza symptoms. The alleviation of influenza symptoms is defined as the time when all of 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) have been assessed by the patient as being alleviated at each prespecified time point.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 24, 2019)
  • Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo [ Time Frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.
  • Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.
  • Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to Baloxavir or Placebo [ Time Frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.
  • Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Influenza virus RNA was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.
  • Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo [ Time Frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
  • Change From Baseline in Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
  • Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to Baloxavir or Placebo [ Time Frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).
  • Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).
  • Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo [ Time Frame: Day 1 to Day 9 ]
    This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
  • Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Day 1 to Day 9 ]
    This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
  • Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo [ Time Frame: Day 1 to Day 9 ]
    This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
  • Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Day 1 to Day 9 ]
    This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
  • Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo [ Time Frame: Day 1 to Day 9 ]
    Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
  • Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Day 1 to Day 9 ]
    Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
  • Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo [ Time Frame: Day 1 to Day 9 ]
    Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
  • Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Day 1 to Day 9 ]
    Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
  • Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to Baloxavir or Placebo [ Time Frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .
  • Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .
  • Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
  • Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
  • Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
  • Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
  • Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to Baloxavir or Placebo [ Time Frame: Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment. ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.
  • Change From Baseline in Composite Symptom Score at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment. ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.
  • Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo [ Time Frame: Initiation of study treatment up to Day 14 ]
    Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
  • Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Initiation of study treatment up to Day 14 ]
    Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
  • Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo [ Time Frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment ]
    Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.
  • Percentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment ]
    Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.
  • Body Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo [ Time Frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment ]
    Participant's self-measured axillary temperature using an electronic thermometer.
  • Body Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment ]
    Participant's self-measured axillary temperature using an electronic thermometer.
  • Time to Alleviation of Individual Symptoms in Participants Randomized to Baloxavir or Placebo [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
  • Time to Alleviation of Individual Symptoms in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
  • Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and your health condition]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
  • Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and your health condition]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
  • Percentage of Participants With Influenza-related Complications in Participants Randomized to Baloxavir or Placebo [ Time Frame: Initiation of study treatment up to Day 14 ]
    The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.
  • Percentage of Participants With Influenza-related Complications in Adults Randomized to Baloxavir or Oseltamivir [ Time Frame: Initiation of study treatment up to Day 14 ]
    The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.
  • Percentage of Participants With Adverse Events (AEs) [ Time Frame: From first dose of study drug to Day 22 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: November 1, 2016)
  • Percentage of participants positive for influenza virus titer at each time point [ Time Frame: Days 1, 2, 3, 5 and 9 ]
    Defined as the percentage of patients whose virus titer is not less than the lower limit of quantification among those assessed for virus titer.
  • Percentage of participants positive for influenza virus by RT-PCR at each time point [ Time Frame: Days 1, 2, 3, 5 and 9 ]
    Defined as the percentage of patients with detectable virus ribonucleic acid (RNA) measured by reverse transcription polymerase chain reaction (RT-PCR).
  • Change from baseline in virus titer at each time point [ Time Frame: From Day 1 pretreatment to Days 2, 3, 5, and 9 ]
    Virus titer is measured by tissue culture.
  • Change from baseline in virus RNA (RT-PCR) at each time point [ Time Frame: From Day 1 pretreatment to Days 2, 3, 5, and 9 ]
    Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).
  • Area under the curve (AUC) adjusted by baseline in virus titer [ Time Frame: Day 1 to Day 9 ]
    Defined as AUC of change from baseline in virus titer. The AUC is calculated using the trapezoidal method.
  • Area under the curve (AUC) adjusted by baseline of virus RNA [ Time Frame: Day 1 to Day 9 ]
    Defined as AUC of change from baseline in virus RNA. The AUC is calculated using the trapezoidal method.
  • Time to cessation of viral shedding by virus titer [ Time Frame: Day 1 to Day 9 ]
    Defined as the time between the initiation of the study treatment and first time when the virus titer is below the limit of quantification (BLQ).
  • Time to cessation of viral shedding by virus RNA [ Time Frame: Day 1 to Day 9 ]
    Defined as the time between the initiation of the study treatment and first time when the virus RNA is below the limit of quantification (BLQ) measured by RT-PCR
  • Percentage of participants whose symptoms have been alleviated at each time point [ Time Frame: Days 2, 3, 4, 5, 6, 9, and 15 ]
  • Time to alleviation of the 4 systemic symptoms [ Time Frame: Initiation of study treatment up to Day 14 ]
    Defined as the time between the initiation of the study treatment and the alleviation of the 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue).
  • Time to alleviation of the 3 respiratory symptoms [ Time Frame: Initiation of study treatment up to Day 14 ]
    Defined as the time between the initiation of the study treatment and the alleviation of the 3 respiratory symptoms (cough, sore throat and nasal congestion).
  • Change from baseline in composite symptom score at each time point [ Time Frame: Day 1 pretreatment to morning and evening on Days 2 to 9 and evening on Days 10 to 14 ]
    Defined as the change from Day 1 pretreatment (baseline) in the total score of 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) as assessed by the patient.
  • Time to resolution of fever [ Time Frame: Initiation of study treatment up to Day 14 ]
    Defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever is defined as the time when the patient's self-measured axillary temperature becomes less than 37ºC.
  • Percentage of participants reporting normal temperature at each time point [ Time Frame: Days 1 to 3 at morning, noon, evening and bedtime, Days 4 to 14 morning and evening ]
    Defined as the percentage of patients whose axillary temperature drops to less than 37ºC after the initiation of the study.
  • Body temperature at each time point [ Time Frame: Days 1 to 3 at morning, noon, evening and bedtime, Days 4 to 14 morning and evening ]
  • Time to alleviation of individual symptoms [ Time Frame: Initiation of study treatment up to Day 14 ]
    Defined as the time between the initiation of the study treatment and the alleviation of individual symptoms.
  • Time to return to preinfluenza health status [ Time Frame: Initiation of study treatment up to Day 14 ]
    Patients will be asked to record their preinfluenza health status (for someone your age and your health condition). Return to preinfluenza health status is defined as time from the initiation of the study treatment to the time to return to preinfluenza health status.
  • Percentage of participants with influenza-related complications [ Time Frame: Initiation of study treatment up to Day 14 ]
    Defined as the percentage of patients in the analysis population who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.
  • Number of participants with adverse events (AEs) [ Time Frame: Day 1 to Day 22 plus or minus 3 days ]
    The incidence of AEs in patients with influenza after S-033188, after oseltamivir, and after placebo.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Official Title  ICMJE A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Brief Summary The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus infection.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Influenza
Intervention  ICMJE
  • Drug: Baloxavir Marboxil
    2 to4 X 20-mg tablets taken orally
    Other Name: S-033188
  • Drug: Placebo to Baloxavir Marboxil
    2 to4 X 20-mg tablets taken orally
  • Drug: Oseltamivir
    75 mg capsules taken orally
    Other Name: Tamiflu®
  • Drug: Placebo to Oseltamivir
    Placebo capsules matching oseltamivir 75 mg capsules
Study Arms  ICMJE
  • Experimental: Adults: Baloxavir Marboxil
    Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
    Interventions:
    • Drug: Baloxavir Marboxil
    • Drug: Placebo to Oseltamivir
  • Active Comparator: Adults: Oseltamivir
    Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
    Interventions:
    • Drug: Placebo to Baloxavir Marboxil
    • Drug: Oseltamivir
  • Placebo Comparator: Adults: Placebo
    Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
    Interventions:
    • Drug: Placebo to Baloxavir Marboxil
    • Drug: Placebo to Oseltamivir
  • Experimental: Adolescents: Baloxavir Marboxil
    Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
    Intervention: Drug: Baloxavir Marboxil
  • Placebo Comparator: Adolescents: Placebo
    Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
    Intervention: Drug: Placebo to Baloxavir Marboxil
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 3, 2018)
1436
Original Estimated Enrollment  ICMJE
 (submitted: November 1, 2016)
1494
Actual Study Completion Date  ICMJE April 24, 2017
Actual Primary Completion Date April 4, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately. As for adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements
  2. Male or female patients aged ≥ 12 to ≤ 64 years at the time of signing the informed consent/assent form.
  3. Patients with a diagnosis of influenza virus infection confirmed by all of the following:

    1. Fever ≥ 38ºC (axillary) in the predose examinations or > 4 hours after dosing of antipyretics if they were taken
    2. At least one of the following general systemic symptoms associated with influenza are present with a severity of moderate or greater

      • Headache
      • Feverishness or chills
      • Muscle or joint pain
      • Fatigue
    3. At least one of the following respiratory symptoms associated with influenza are present with a severity of moderate or greater

      • Cough
      • Sore throat
      • Nasal congestion
  4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:

    1. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
    2. Time when the patient experiences at least one general or respiratory symptom
  5. Women of childbearing potential who agree to use a highly effective method of contraception for 3 months after the first dose of study drug

Exclusion Criteria:

  1. Patients with severe influenza virus infection requiring inpatient treatment.
  2. Patients aged ≥ 20 years with known allergy to oseltamivir (Tamiflu®).
  3. Patients with any of the following risk factors

    1. Women who are pregnant or within 2 weeks post-partum
    2. Residents of long-term care facilities (eg, welfare facilities for the elderly, nursing homes)
    3. Chronic respiratory diseases including bronchial asthma
    4. Neurological and neurodevelopmental disorders including disorders of the brain, spinal cord, peripheral nerve, and muscle (eg, cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
    5. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms)
    6. American Indians and Alaskan natives
    7. Blood disorders (such as sickle cell disease)
    8. Endocrine disorders (including diabetes mellitus)
    9. Kidney disorders
    10. Liver disorders
    11. Metabolic disorders
    12. Compromised immune system (including patients receiving immunosuppressant therapy, or those with cancer or human immunodeficiency virus [HIV] infection)
    13. Morbid obesity (body mass index [BMI] ≥ 40)
  4. Patients unable to swallow tablets or capsules.
  5. Patients who have previously received Baloxavir Marboxil.
  6. Patients weighing < 40 kg
  7. Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.
  8. Women who are breastfeeding or have a positive pregnancy test in the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test in the predose examinations:

    1. Postmenopausal (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test) women
    2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
  9. Patients with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at the predose examinations.
  10. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, or amantadine within 30 days prior to the predose examinations.
  11. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
  12. Patients with severe underlying diseases.
  13. Patients with known creatinine clearance ≤ 60 mL/min.
  14. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years to 64 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries Canada,   Japan,   Korea, Republic of,   Singapore,   Thailand,   United States
 
Administrative Information
NCT Number  ICMJE NCT02954354
Other Study ID Numbers  ICMJE 1601T0831
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Shionogi Inc. ( Shionogi )
Study Sponsor  ICMJE Shionogi
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Support Help Line Shionogi Clinical Trials Administrator Shionogi
PRS Account Shionogi Inc.
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP